Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
DPP4 inhibitors are used for the treatment of diabetes, but the impact of DPP4 activity and soluble DPP4 on development of diabetes-associated inflammation remains uncertain. Here the authors study whether DPP4 inhibition controls sDPP4 and inflammatory biomarkers, and demonstrate that DPP4 inhibiti...
Guardado en:
Autores principales: | Laurie L. Baggio, Elodie M. Varin, Jacqueline A. Koehler, Xiemin Cao, Yuliya Lokhnygina, Susanna R. Stevens, Rury R. Holman, Daniel J. Drucker |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cfbe57d96821439588f72940834dce14 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Isolation of MERS-related coronavirus from lesser bamboo bats that uses DPP4 and infects human-DPP4-transgenic mice
por: Susanna K. P. Lau, et al.
Publicado: (2021) -
Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Radha Andukuri, et al.
Publicado: (2009) -
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto M
Publicado: (2013) -
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz B
Publicado: (2013) -
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahrén
Publicado: (2010)